natgillin/translations-raw huggingface dataset:
Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. 
Kandesartan se ne veže oz. ne zavira drugih hormonskih receptorjev ali ionskih kanalčkov, pomembnih za kardiovaskularno regulacijo.
Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while renal vascular resistance and filtration fraction are reduced. 
Kandesartan poveča pretok krvi skozi ledvice in bodisi ne vpliva na hitrost glomerularne filtracije ali pa jo poveča, medtem ko sta ledvični žilni upor in filtracijska frakcija zmanjšana.
This belongs to a group of medicines called angiotensin II receptor antagonists. 
Ta učinkovina spada v skupino zdravil, ki jih imenujemo antagonisti receptorjev angiotenzina II.
Results from two clinical studies investigating the pharmacokinetic (PK) profile of candesartan in patients with impaired hepatic function and the publication by Hoogkamer et al 1998, where a starting dose of 12 mg was used, indicate that mild to moderate hepatic impairment has no relevant effect on candesartan PK, and thus no dose adjustment is required. 
Rezultati dveh kliničnih študij, v katerih so preučevali farmakokinetični profil kandesartana pri bolnikih z okvaro jeter, in objava študije Hoogkamer et al 1998, v kateri so uporabili začetni odmerek 12 mg, kažejo, da blaga do zmerna okvara jeter nima pomembnega vpliva na farmakokinetiko kandesartana, zato prilagajanje odmerka ni potrebno.
Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders. 
Angiotenzin II je primarni vazoaktivni hormon sistema renin-angiotenzin-aldosteron in ima vlogo v patofiziologiji hipertenzije, srčnega popuščanja in drugih kardiovaskularnih bolezni.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
Very rare Leukopenia, neutropenia and agranulocytosis 
Zelo redki levkopenija, nevtropenija in agranulocitoza
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EUROPEAN MEDICINE AGENCY 
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODILA ZA UPORABO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
Caution should be observed when initiating therapy and correction of hypovolemia should be attempted. 
Pri uvedbi zdravljenja je potrebna previdnost in hipovolemijo je treba poskusiti korigirati.
If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. 
Če to ne zadošča, je treba povečati volumen plazme z infuzijo, npr. z infuzijo fiziološke raztopine.
C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite. 
26 % odmerka izloči v urinu kot kandesartan in 7 % kot neaktivni presnovek, približno 56 % odmerka pa se pojavi v blatu kot kandesartan in 10 % kot neaktivni presnovek.
Atacand may also be administered with other antihypertensive agents. 
Atacand se lahko uporablja tudi z drugimi antihipertenzivi.
The CHMP noted that there is plausible effect based on the pharmacologic action of the drug to affect the ability to drive thus this section was harmonised to reflect that ‘dizziness' and ‘weariness' can occur. 
CHMP je ugotovil, da je zaradi farmakološkega delovanja zdravila možen učinek na sposobnost vožnje, zato je bilo to poglavje usklajeno tako, da odraža možnost pojava „omotice“ in „utrujenosti.“
Periodic monitoring of serum creatinine and potassium is recommended (see section 4.4). 
Priporočljive so redne kontrole kreatinina in kalija v serumu (glejte poglavje 4.4).
The use of AIIRAs in the second and third trimester is contraindicated. 
Uporaba antagonistov AIIRA v drugem in tretjem trimesečju nosečnosti je kontraindicirana.
Very rare Increased liver enzymes, abnormal hepatic function or hepatitis 
Zelo redki zvišanje jetrnih encimov, nenormalno delovanje jeter ali hepatitis
There is no experience in patients with severe hepatic impairment. 
Izkušenj pri bolnikih s hudo okvaro jeter ni.
Germany AstraZeneca GmbH 22876 Wedel, Germany 
AstraZeneca GmbH 22876 Wedel Germany
The adverse experience profile of Atacand in heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. 
Značilnosti neželenih učinkov Atacanda pri bolnikih s srčnim popuščanjem so se skladali s farmakologijo zdravila in zdravstvenim stanjem bolnikov.
- An increased amount of potassium in your blood, especially if you already have kidney problems or heart failure. 
- Več kalija v krvi, zlasti če že imate težave z ledvicami ali srčno popuščanje.
Use of candesartan with lithium is not recommended. 
Sočasna uporaba kandesartana in litija ni priporočljiva.
Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic hypotension and dizziness. 
Na podlagi farmakologije sta najverjetnejša glavna znaka prevelikega odmerjanja simptomatska hipotenzija in omotica.
There is no experience with the use of Atacand in children (below the age of 18 years). 
Pri otrocih (mlajših od 18 let) ni izkušenj z uporabo zdravila Atacand.
• When you are prescribed Atacand, discuss with your doctor before drinking alcohol. 
• Ko vam predpišejo zdravilo Atacand se morate glede pitja alkoholnih pijač posvetovati z zdravnikom.
In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). 
V dveh študijah, ki sta vključevali bolnike z blago do zmerno okvaro jeter so ugotovili povečanje povprečne AUC kandesartana za približno 20 % v eni in 80 % v drugi študiji (glejte poglavje 4.2).
Data from in vitro and in vivo mutagenicity testing indicates that candesartan will not exert mutagenic or clastogenic activities under conditions of clinical use. 
Podatki testiranja mutagenosti in vitro in in vivo kažejo, da kandesartan v pogojih klinične uporabe ne deluje mutageno ali klastogeno.
Atacand contains lactose. 
Atacand vsebuje laktozo.
In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. 
Pri hipertenziji kandesartan povzroči od odmerka odvisno, dolgotrajno znižanje arterijskega krvnega tlaka.
Atacand is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Zdravila Atacand ne priporočamo v zgodnji nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, saj lahko resno poškoduje vašega otroka, če ga uporabljamo v tem obdobju (glejte poglavje o nosečnosti).
Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. 
Zelo redko je lahko hipotenzija tako huda, da mora bolnik dobiti intravensko tekočino in/ali vazokonstriktorje.
Based on the above the CHMP considers the benefit/risk ratio of Atacand to be favourable and the harmonised PI to be approvable. 
Na osnovi navedenega je CHMP menil, da je razmerje med koristmi in tveganji za zdravilo Atacand ugodno in da je usklajeno navodilo za uporabo mogoče odobriti.
When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. 
Če so AIIRA uporabljeni sočasno z nesteroidnimi protivnetnimi zdravili (NSAID) (tj. selektivnimi zaviralci COX-2, acetilsalicilno kislino (> 3 g/dan) ali neselektivnimi nesteroidnimi protivnetnimi zdravili), se lahko antihipertenzivni učinek zmanjša.
Section 4.6 Pregnancy and Lactation 
Poglavje 4.6 Nosečnost in dojenje
Patients who respond with some reduction in blood pressure to candesartan monotherapy at lower doses may have further advantage of the full 32 mg dose. 
Bolniki, ki se na monoterapijo z manjšimi odmerki kandesartana odzovejo z določenim znižanjem krvnega tlaka, lahko dodatno izkoristijo celoten odmerek 32 mg.
Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%). 
Delež prekinitev zdravljenja zaradi neželenih učinkov je bil s cileksetilkandesartanatom (3,1 %) podoben kot s placebom (3,2 %).
A reduced amount of sodium in your blood. 
Manj natrija v krvi.
Monitoring of potassium should be undertaken as appropriate. 
Koncentracijo kalija je treba kontrolirati, kot je primerno.
If this is severe then you may notice weakness, lack of energy, or muscle cramps. 
Če je to zmanjšanje hudo, lahko občutite šibkost, pomanjkanje energije ali mišične krče.
By this definition, the most commonly reported adverse reactions were dizziness/vertigo, headache and respiratory infection. 
Po tej opredelitvi so bili najpogostejši neželeni učinki omotica/vrtoglavica, glavobol in okužba dihal.
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke. 
Kot velja za vsa antihipertenzivna zdravila, lahko čezmerno znižanje krvnega tlaka pri bolnikih z ishemično kardiopatijo ali ishemično cerebrovaskularno boleznijo izzove miokardni infarkt ali možgansko kap.
However, reference to an increased antihypertensive effect when candesartan cilexetil is combined with a CCB amlodipine or felodipine was not included in section 4.2 but rather in 5.1. 
Vendar je bil sklic na povečanje antihipertenzivnega učinka kombiniranja kandesartan cileksetila z zaviralcem kalcijevih kanalčkov amlodipinom ali felodipinom vključen v poglavje 5.1 in ne v poglavje 4.2.
The terminal t½ of candesartan was approximately doubled in patients with severe renal impairment. 
Terminalni t1/2 kandesartana se je pri bolnikih s hudo okvaro ledvic približno podvojil.
The recommended starting dose and usual maintenance dose of candesartan is 8 mg. 
Priporočljiv začetni odmerek in običajni vzdrževalni odmerek kandesartana sta 8 mg.
The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). 
Uporaba AIIRA ni priporočljiva v prvem trimesečju nosečnosti (glejte poglavje 4.4).
There is no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trials comparing candesartan with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. 
Ne vpliva na ACE in ne stopnjuje delovanja bradikinina ali snovi P. V kontroliranih kliničnih preskušanjih, ki so primerjala kandesartan z zaviralci ACE, je bila incidenca kašlja manjša pri bolnikih, ki so prejemali cileksetilkandesartanat.
If you forget to take Atacand Do not take a double dose to make up for a forgotten tablet. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjo tableto.
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started. 
Ko je nosečnost potrjena, moramo zdravljenje z AIIRA takoj prekiniti in če je primerno začeti z nadomestnim zdravljenjem.
Alcohol may make you feel faint or dizzy. 
Alkohol vam lahko povzroči omotico ali omedlevico.
An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see section 4.4). 
Začetni odmerek 4 mg pride v poštev pri bolnikih s tveganjem za hipotenzijo, npr. pri bolnikih z možno hipovolemijo (glejte poglavje 4.4).
Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4). 
Dojenčke, katerih matere so bile izpostavljene AIIRA moramo opazovati zaradi hipotenzije (glejte poglavji 4.3 in 4.4).
Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril. 
Med učinkovinami, ki so jih raziskali v kliničnih farmakokinetičnih študijah, so hidroklorotiazid, varfarin, digoksin, peroralni kontraceptivi (tj. etinilestradiol/levonorgestrel), glibenklamid, nifedipin in enalapril.
• Effects on how your kidneys work, especially if you already have kidney problems or heart failure. 
• Vpliv na delovanje ledvic, zlasti če že imate težave z ledvicami ali srčno popuščanje.
Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. 
Odpornost proti okužbam se zato lahko zmanjša in opazite lahko utrujenost, okužbo ali zvišano telesno temperaturo.
Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin-aldosterone system. 
Bolniki s primarnim aldosteronizmom se praviloma ne odzovejo na antihipertenzivna zdravila, ki delujejo z zavrtjem sistema renin-angiotenzin-aldosteron.
During dialysis the blood pressure may be particularly sensitive to AT1-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. 
Med dializo je lahko krvni tlak še posebej občutljiv za blokado receptorjev AT1, in sicer zaradi zmanjšanega volumna plazme in aktiviranja sistema renin-angiotenzin-aldosteron.
The name of your medicine is Atacand. 
Vaše zdravilo se imenuje Atacand.
Based on the information provided, the CHMP endorsed the harmonised text for Angiotensin II receptor antagonists as the standard warning elaborated by the CHMP's Pharmacovigilance Working Party for all Angiotensin II receptor antagonists (AIIRAs): the use of AIIRAs in the first trimester of pregnancy is not recommended; the use of AIIRAs in the second and third trimester is contraindicated. 
CHMP je na osnovi predloženih podatkov kot usklajeno besedilo za antagoniste receptorjev angiotenzina II potrdil standardno opozorilo, ki ga je za antagoniste receptorjev za angiotenzin II (AIIRA) pripravila delovna skupina CHMP za farmakovigilanco: uporaba antagonistov AIIRA v prvem trimesečju nosečnosti ni priporočljiva, uporaba v drugem in tretjem trimesečju je kontraindicirana.
When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. 
Če je cileksetilkandesartanat uporabljen skupaj s hidroklorotiazidom, je znižanje krvnega tlaka aditivno.
It may also occur in hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics. 
Pojavi se lahko tudi pri hipertenzivnih bolnikih s hipovolemijo, npr. bolnikih, ki dobivajo velike odmerke diuretikov.
Therefore Atacand should not be given to children. 
Zato otroci ne smejo dobivati zdravila Atacand.
What Atacand is and what it is used for Before you take Atacand How to take Atacand Possible side effects How to store Atacand Further information 
Kaj je zdravilo Atacand in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Atacand Kako jemati zdravilo Atacand Možni neželeni učinki
This medicinal product was considered for SPC harmonisation and a referral was triggered in order to resolve divergences and harmonise the nationally authorised product information (PI) across Europe. 
Za zdravilo je bilo načrtovano usklajevanje povzetkov glavnih značilnosti zdravila, zato je bil uveden napotitveni postopek, da bi se razrešile razlike in uskladile nacionalno odobrene informacije o zdravilu v Evropi.
However, patients treated with candesartan, an ACE inhibitor and a potassium sparing diuretic experienced increased risk of hyperkalaemia. 
Vendar se je pri bolnikih, ki so bili zdravljeni s kandesartanom, zaviralcem ACE in diuretikom, ki varčuje s kalijem, povečalo tveganje hiperkaliemije.
The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on COgnition and Prognosis in the Elderly). 
Učinke odmerkov od 8 do 16 mg cileksetilkandesartanata (povprečni odmerek 12 mg) enkrat na dan na kardiovaskularno obolevnost in umrljivost so ocenili v randomiziranem kliničnem preskušanju pri 4.937 starejših bolnikih (starih od 70 do 89 let, 21 % starih 80 let ali več) z blago do zmerno hipertenzijo; bolnike so spremljali povprečno 3,7 leta (študija SCOPE; Study on COgnition and Prognosis in the Elderly).
Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive effect in black patients (usually a low-renin population) than in non-black patients. 
Zdravila, ki blokirajo sistem renin-angiotenzin-aldosteron, imajo pri bolnikih-črncih manj izrazit antihipertenzivni učinek (po navadi gre za populacijo z nizkim reninom) kot pri bolnikih-nečrncih.
The CHMP also agreed with the inclusion of a contraindication in patients with hypersensitivity to candersartan or to any of its excipients and in patients with severe hepatic impairment and/or cholestasis. 
CHMP se je tudi strinjal z vključitvijo kontraindikacije pri bolnikih s preobčutljivostjo za kandesartan ali katero koli pomožno snov ter pri bolnikih s hudo jetrno okvaro ali holestazo ali obojim.
Very rare Nausea 
Zelo redki navzea
Luxembourg NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels 
Luksemburg NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels
If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Atacand. 
Če niste prepričani, ali kaj od tega velja za vas, se posvetujte z zdravnikom ali s farmacevtom, preden vzamete zdravilo Atacand.
• Headache. 
• Glavobol.
The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure lowering properties, whether prescribed as an antihypertensive or prescribed for other indications. 
Antihipertenziven učinek kandesartana lahko povečajo zdravila, ki znižujejo krvni tlak, bodisi da so predpisana za zniževanje krvnega tlaka ali za druge indikacije.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. 
Razen, če je nadaljevanje z AIIRA nujno, morajo bolnice, ki načrtujejo nosečnost, preiti na antihipertenzivno zdravljenje, ki ima dokazan varnostni profil za uporabo med nosečnostjo.
The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. 
Absolutna biološka uporabnost kandesartana je po uporabi peroralne raztopine cileksetilkandesartanata približno 40 %.
In a 3-month clinical study in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95%CI 15-42%). 
V 3-mesečni klinični študiji pri hipertenzivnih bolnikih s sladkorno boleznijo tipa 2 in mikroalbuminurijo je antihipertenzivno zdravljenje s cileksetilkandesartanatom zmanjšalo izločanje albumina v urinu (razmerje albumin/kreatinin, povprečje 30 %, 95 % IZ: od 15 do 42 %).
The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. 
V ledvicah se kandesartan izloča z glomerularno filtracijo in aktivno tubularno sekrecijo.
Sections on use in special populations, such as elderly, patients with intravascular volume depletion, patients with impaired renal and hepatic function and patients of black ethnicity were also harmonised. 
Usklajena so bila tudi poglavja o uporabi pri posebnih populacijah, kot so starostniki, bolniki z zmanjšanim intravaskularnim volumnom, bolniki z motnjami v delovanju ledvic in jeter ter bolniki črne rase.
No gender related differences in the pharmacokinetics of candesartan have been observed. 
V farmakokinetiki kandesartana niso ugotovili s spolom povezanih razlik.
Fourteen patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. 
Med trajanjem študije je bilo treba zdraviti 14 bolnikov, da bi preprečili smrt enega bolnika zaradi kardiovaskularnega dogodka ali hospitalizacijo za zdravljenje srčnega popuščanja.
• Lithium (a medicine for mental health problems). 
• litij (zdravilo za duševne motnje).
The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g. spironolactone) and Atacand is not recommended and should be considered only after careful evaluation of the potential benefits and risks (see sections 4.4, 4.8 and 5.1). 
Kombinacija zaviralca ACE, diuretika, ki varčuje s kalijem (npr. spironolaktona) in zdravila Atacand ni priporočljiva in pride v poštev šele po natančni oceni možnih koristi in tveganj (glejte poglavja 4.4, 4.8 in 5.1).
Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. 
Če je prišlo do izpostavljenosti AIIRA v drugem trimesečju nosečnosti, je priporočljivo ultrazvočno pregledati delovanje ledvic in lobanjo.
An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or felodipine. 
Večji antihipertenzivni učinek je opazen tudi med uporabo cileksetilkandesartanata v kombinaciji z amlodipinom ali felodipinom.
Atacand can be administered with other heart failure treatment, including ACE inhibitors, beta-blockers, diuretics and digitalis or a combination of these medicinal products. 
Atacand se lahko uporablja skupaj z drugimi zdravili za srčno popuščanje, vključno z zaviralci ACE, zaviralci adrenergičnih receptorjev beta, diuretiki in digitalisom ali kombinacijo teh zdravil.
In general, there were no clinically important influences of Atacand on routine laboratory variables. 
Na splošno Atacand ni klinično pomembno vplival na običajne laboratorijske vrednosti.
Candesartan was effective also in patients taking both beta-blockers and ACE inhibitors at the same time, and the benefit was obtained whether or not patients were taking ACE inhibitors at the target dose recommended by treatment guidelines. 
Kandesartan je bil učinkovit tudi pri bolnikih, ki so hkrati prejemali zaviralce adrenergičnih receptorjev beta in zaviralce ACE, koristni učinki pa so bili neodisni od tega, ali so bolniki zaviralce ACE jemali v ciljnih odmerkih, priporočenih v smernicah za zdravljenje.
The SPC in one MS mentioned the addition of a calcium channel blocker (CCB) as an additional alternative strategy. 
V povzetku glavnih značilnosti zdravila v eni državi članici se kot dodatna alternativna strategija omenja dodatek zaviralca kalcijevih kanalčkov.
Elderly population No initial dose adjustment is necessary in elderly patients. 
Starejša populacija Starejšim bolnikom začetnega odmerka ni treba prilagoditi.
Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure, and improves symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
Zdravljenje s cileksetilkandesartanatom zmanjša umrljivost, zmanjša hospitalizacije zaradi srčnega popuščanja in izboljša simptome pri bolnikih z blago do zmerno sistolično disfunkcijo levega prekata, kot je pokazal program CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity).